Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

MRD-geadapteerde lage-dosis radiotherapie tijdens eerstelijns chemo-immunotherapie voor diffuus grootcellig lymfoom (MRD-XRT)

4 november 2026 bijgewerkt door: University of Nebraska

Haalbaarheid van MRD-Adaptieve Middelcyclus Lage-Dosis Straling Gecombineerd Met Eerstelijns R-Chemo-immunotherapie Bij Diffuus Grootcellig B-Cellymfoom (MRD XRT)

This prospective Phase IIA feasibility study evaluates a minimal residual disease (MRD)-adapted treatment strategy in patients with diffuse large B-cell lymphoma (DLBCL) receiving frontline R-chemoimmunotherapy. Circulating tumor DNA (ctDNA)-based MRD testing and interim positron emission tomography (PET) imaging after two cycles of therapy are used to guide treatment decisions. Patients with detectable MRD and residual PET-avid or measurable disease suitable for radiation therapy receive protocol-directed low-dose radiation therapy (LDRT) in addition to standard systemic therapy. Patients with undetectable MRD, or detectable MRD without targetable residual disease, continue standard frontline chemoimmunotherapy without protocol-directed LDRT.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Diffuse large B-cell lymphoma (DLBCL) is commonly treated with frontline R-chemoimmunotherapy regimens such as R-CHOP or related combinations. Interim positron emission tomography (PET) imaging provides information about treatment response, while circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) testing allows assessment of molecular residual disease during treatment.

This prospective, non-randomized Phase IIA feasibility study evaluates the integration of ctDNA-based MRD testing and interim PET imaging into frontline treatment decisions for patients with DLBCL. Approximately 50 participants are expected to enroll.

Following two cycles of frontline R-chemoimmunotherapy, participants undergo protocol-specified MRD testing and interim PET assessment. Participants with detectable MRD and residual PET-avid or measurable disease suitable for radiation therapy are assigned to Arm A and receive protocol-directed low-dose radiation therapy (LDRT) in addition to standard frontline chemoimmunotherapy.

Participants with undetectable MRD, as well as those with detectable MRD but without targetable residual disease, are assigned to Arm B and continue standard frontline chemoimmunotherapy without protocol-directed LDRT.

The primary objective is to evaluate the feasibility of this MRD-adapted strategy, including successful completion of MRD testing after cycle 2 and delivery of protocol-directed LDRT to eligible MRD-positive participants. Secondary assessments include treatment response, progression-free survival, overall survival, the impact of LDRT on systemic treatment delivery, and patient-reported quality of life.

Studietype

Ingrijpend

Inschrijving (Geschat)

50

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

  • Naam: IIT Office Clinical Trails Office
  • Telefoonnummer: (402) 5590963
  • E-mail: IITOFFICE@unmc.edu

Studie Locaties

    • Nebraska
      • Omaha, Nebraska, Verenigde Staten, 68198
        • Fred & Pamela Buffet Cancer Center
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

19 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Adults ≥19 years of age
  2. Biopsy-proven newly diagnosed DLBCL, transformed from indolent lymphoma, Follicular lymphoma grade 3B, post-transplant lymphoproliferative disorder, or any other subtypes of Large B-cell lymphoma under WHO-HAEM5 classification who are eligible and plan to receive 6 cycles of R-chemoimmunotherapy. Note: patients may receive up to one cycle of R-chemoimmunotherapy prior to enrollment.
  3. Planned to receive 6 cycles of frontline R-chemoimmunotherapy for diseases mentioned in criterion 2
  4. Presence of measurable disease on imaging, nodal lesion >1.5cm or extra-nodal lesion >1 cm prior to initiation of R-chemoimmunotherapy
  5. Availability of sufficient and viable baseline FFPE tumor tissue to allow development of a personalized MRD assay

Exclusion Criteria:

  1. Limited stage (Ann Arbor stage I-II) DLBCL, requiring less than 6 cycles of R-chemoimmunotherapy
  2. Primary or secondary CNS lymphoma
  3. Subject has exceeded maximum lifelong cumulative doses of radiation therapy or is unsafe for radiation therapy as determined by the investigator and/or radiation oncologist
  4. Pregnant and lactating patients
  5. Has received two or more cycles of R-chemoimmunotherapy relating to this disease

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Arm- A: MRD-Detectable with Protocol-Directed LDRT

Participants with detectable circulating tumor DNA minimal residual disease (ctDNA MRD) after cycle 2 of frontline R-chemoimmunotherapy and residual PET-avid or measurable disease suitable for radiation therapy receive protocol-directed low-dose radiation therapy (LDRT) to targetable residual disease sites in addition to standard frontline chemoimmunotherapy.

Low-dose radiation therapy delivered to residual PET-avid disease sites identified after interim assessment with PET imaging and MRD testing.

Standard-of-care frontline chemoimmunotherapy regimens for diffuse large B-cell lymphoma, including R-CHOP, Pola-R-CHP, DA-EPOCH-R, R-CEOP, or related regimens as determined by the treating physician.

Actieve vergelijker: Arm B: Standard Therapy Without Protocol-Directed LDRT

Participants with undetectable circulating tumor DNA minimal residual disease (ctDNA MRD) after cycle 2 of frontline R-chemoimmunotherapy, or participants with detectable MRD but without residual PET-avid or measurable disease suitable for radiation therapy, continue standard frontline chemoimmunotherapy without protocol-directed low-dose radiation therapy (LDRT).

Standard-of-care frontline chemoimmunotherapy regimens for diffuse large B-cell lymphoma, including R-CHOP, Pola-R-CHP, DA-EPOCH-R, R-CEOP, or related regimens as determined by the treating physician.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Feasibility of Real-Time MRD-Guided Treatment Strategy
Tijdsspanne: From interim MRD assessment after Cycle 2 through completion of protocol-directed low-dose radiation therapy (LDRT) before Cycle 5 Day 1 (approximately 12 weeks after treatment initiation).

Feasibility will be assessed by the proportion of enrolled patients who successfully complete protocol-specified MRD testing after two cycles of chemoimmunotherapy and, among patients with detectable MRD, the proportion who successfully receive protocol-defined low-dose radiation therapy (LDRT). Feasibility will be considered acceptable if at least 80% of enrolled patients complete MRD testing and at least 80% of ctDNA-positive patients receive LDRT.

From interim MRD assessment after Cycle 2 through completion of protocol-directed low-dose radiation therapy (LDRT) before Cycle 5 Day 1 (approximately 12 weeks after treatment initiation).

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Overall response rate (ORR), Including Complete Response (CR) and Partial Response (PR) Rates
Tijdsspanne: At end-of-treatment response assessment following completion of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).

The proportion of participants achieving complete response (CR) or partial response (PR), with complete response rate assessed separately. Response will be evaluated using PET/CT imaging according to Lugano 2014 criteria.

At end-of-treatment response assessment following completion of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
Progression-Free Survival (PFS)
Tijdsspanne: From initiation of frontline therapy until disease progression or death, with follow-up for approximately 2 years after completion or discontinuation of treatment.

Progression-free survival is defined as the time from initiation of frontline therapy until disease progression or death from any cause. PFS will be estimated using the Kaplan-Meier method.

From initiation of frontline therapy until disease progression or death, with follow-up for approximately 2 years after completion or discontinuation of treatment.
Overall Survival (OS)
Tijdsspanne: From initiation of frontline therapy until death from any cause, with follow-up for approximately 2 years after completion or discontinuation of treatment.

Overall survival is defined as the time from initiation of frontline therapy until death from any cause. OS will be estimated using the Kaplan-Meier method.

From initiation of frontline therapy until death from any cause, with follow-up for approximately 2 years after completion or discontinuation of treatment.
Impact of Low-Dose Radiation Therapy on Delivery of Systemic Chemoimmunotherapy
Tijdsspanne: From initiation of protocol-directed LDRT through completion or discontinuation of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).

The impact of protocol-directed low-dose radiation therapy (LDRT) on the delivery of planned systemic chemoimmunotherapy will be assessed by treatment delays, dose reductions, omitted chemotherapy cycles, or premature discontinuation of systemic therapy attributable to LDRT.

From initiation of protocol-directed LDRT through completion or discontinuation of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
Tijdsspanne: At the end of treatment (end of Cycle 6 of frontline chemoimmunotherapy, approximately 6 months after treatment initiation).

Patient-reported quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), evaluating global health status, functional domains, and symptoms.

At the end of treatment (end of Cycle 6 of frontline chemoimmunotherapy, approximately 6 months after treatment initiation).

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Hoofdonderzoeker: Snegha Ananth, MBBS, University of Nebraska

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

12 december 2026

Primaire voltooiing (Geschat)

12 februari 2031

Studie voltooiing (Geschat)

12 februari 2033

Studieregistratiedata

Eerst ingediend

24 maart 2026

Eerst ingediend dat voldeed aan de QC-criteria

3 april 2026

Eerst geplaatst (Werkelijk)

8 april 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

6 november 2026

Laatste update ingediend die voldeed aan QC-criteria

4 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 0342-26-FB

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .